# UNH — slm-full-gpu

## Metadata

ticker: UNH
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: b444cd47122f405c9f3175ccab5621dfc7f36d4745d7bf0d0a3ec77fddd66873
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-gpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 562, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 15.175, "latency_s_total": 15.175, "parse_failure": 0, "prompt_tokens": 3060, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 416, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 11.377, "latency_s_total": 11.377, "parse_failure": 0, "prompt_tokens": 3049, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 134, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 5.887, "latency_s_total": 5.887, "parse_failure": 0, "prompt_tokens": 855, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 107, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.451, "latency_s_total": 4.451, "parse_failure": 0, "prompt_tokens": 849, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 157, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 6.253, "latency_s_total": 6.253, "parse_failure": 0, "prompt_tokens": 487, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 157, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 7.42, "latency_s_total": 7.42, "parse_failure": 0, "prompt_tokens": 641, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 855, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 12.385, "latency_s_total": 12.385, "parse_failure": 0, "prompt_tokens": 1486, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "UNH",
  "company_name": "UnitedHealth Group Incorporated",
  "current_price": 371.9,
  "currency": "USD",
  "market_cap": 333815513088.0,
  "pe_ratio": 23.916397,
  "forward_pe": 16.448336,
  "week_52_high": 461.62,
  "week_52_low": 255.97,
  "revenue": 450525986816.0,
  "net_income": 14122000384.0,
  "profit_margin": 0.03135,
  "dividend_yield": 2.5,
  "sector": "Healthcare",
  "industry": "Healthcare Plans"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-02",
    "summary": "ITEM 1A. RISK FACTORS CAUTIONARY STATEMENTS The statements, estimates, projections or outlook contained in this Annual Report on Form 10-K include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). When used in this Annual Report on Form 10-K and in future filings by us with the SEC, in our news releases, presentations to securities analysts or investors, and in oral statements made by or with the approval of one of our executive officers, the words \u201cbelieve,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cforecast,\u201d \u201coutlook,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cshould\u201d or similar words or phrases are intended to identify such forward-looking statements. These statements are intended to take advantage of the \u201csafe harbor\u201d provisions of the PSLRA"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-10",
    "summary": "ITEM 1A. RISK FACTORS In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, \u201cRisk Factors\u201d of our 2025 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2025 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. There have been no material changes to the risk factors as disclosed in our 2025 10-K. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Issuer Purchases of Equity Securities (a) Second Quarter 2026 For the Month Ended Total Number of Shares Pu"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the Annual Report on Form 10-K for UNH, the key takeaways regarding risk factors and business operations include:

**Financial and Medical Cost Risks**
*   **Profitability Dependence:** The profitability of risk-based products, which generate nearly 80% of total consolidated revenues, relies heavily on the ability to accurately predict, price, and manage medical and administrative costs.
*   **Estimation Variability:** Benefit expense estimates involve significant judgment and variability. Small differences between predicted and actual medical costs or utilization rates can materially impact financial results.
*   **Unrecoverable Cost Increases:** Actual costs often exceed estimates due to factors such as medical cost inflation, increased service utilization, provider billing intensity, pandemics, climate change effects, and the introduction of costly new drugs or technologies. These excess costs typically cannot be recovered through higher premiums during the fixed contract period.
*   **Value-Based Care Challenges:** For Optum Health’s fully accountable value-based arrangements, failure to deliver higher-quality outcomes at lower costs or to successfully integrate care delivery models could adversely affect financial positions and cash flows.

**Technology, Data, and Cybersecurity Risks**
*   **Cybersecurity Threats:** The company faces ongoing risks from cyberattacks, data breaches, and privacy incidents. A notable example cited is a 2024 cyberattack on the acquired Change Healthcare business, which involved protected health information.
*   **Sophisticated Threats:** Threat actors are increasingly using sophisticated techniques, including evolving AI technologies (such as generative AI), to penetrate security controls, deploy malicious code (e.g., ransomware), and disrupt operations.
*   **Data Integrity and Systems:** The business depends on the integrity, timeliness, and availability of data. Inaccurate, incomplete, or outdated data can lead to product failures, loss of customers, pricing errors, fraud issues, and regulatory sanctions.
*   **Integration and Compliance Challenges:** Failure to successfully consolidate, integrate, and upgrade information systems can result in higher-than-expected costs. Additionally, rapidly evolving U.S. and international laws regarding health data and AI may alter the competitive landscape and impose new compliance requirements.
*   **Third-Party and Vendor Risks:** The company relies on third-party vendors for data processing, which introduces risks outside of direct oversight. Recently acquired or non-integrated businesses may also present heightened vulnerabilities.

**Forward-Looking Statements**
*   The report contains forward-looking statements subject to risks and uncertainties that may cause actual results to differ materially from expectations. These statements are not guarantees of future performance and are subject to various known and unknown risks, including those related to business mix, regulatory changes, and insured population characteristics.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Inaccurate Cost Estimation and Management:** Failure to accurately estimate, price, or manage medical costs and benefit design for risk-based products could materially and adversely affect results of operations, financial position, and cash flows. This is particularly relevant because premium revenues from these products constitute nearly 80% of total consolidated revenues. Actual costs may exceed estimates due to factors such as medical cost inflation, increased service utilization, provider billing intensity, pandemics, climate change effects, new or costly drugs, and regulatory changes. Additionally, estimates for outstanding claims involve significant judgment, and inaccuracies could negatively impact financial results.
*   **Data Integrity and Information Systems:** Failure to maintain the integrity, availability, or security of data, or to successfully consolidate, integrate, upgrade, or expand information systems, could materially and adversely affect the business. Risks include data inaccuracy, system failures, difficulty in pricing products, fraud detection issues, regulatory sanctions, and increased operating expenses. The rapid expansion of health care data and the increasing role of artificial intelligence (AI) require significant ongoing resources to keep pace with technological changes.
*   **Cybersecurity and Data Privacy:** Exposure to cyberattacks, privacy breaches, or data security incidents involving protected personal information or proprietary data could result in revenue loss, increased costs, liability, reputational harm, and operational disruptions. The sophistication of threats, including those leveraging AI, and vulnerabilities in third-party vendors or recently acquired businesses (such as the reported 2024 cyberattack on Change Healthcare) present ongoing risks.
*   **Relationships with Health Care Providers:** Failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals, and other service providers could materially and adversely affect the business.
*   **Regulatory and Legal Compliance:** Uncertain and rapidly evolving laws and regulations related to health data and information technologies, including those involving AI, may alter the competitive landscape, impose new compliance requirements, and negatively impact the configuration of information systems and market competitiveness.

## Pre-written sections (judge input)

### Financial Health

UnitedHealth Group (UNH) trades at $371.90 with a substantial market capitalization of approximately $333.8 billion. The stock currently exhibits a trailing P/E ratio of 23.92, which is notably higher than its forward P/E of 16.45, suggesting anticipated earnings growth. The company generates robust annual revenue of $450.5 billion, though it maintains a relatively modest net profit margin of 3.14%. This valuation profile indicates that while the market prices in significant future growth, the current multiple reflects a premium compared to near-term earnings expectations.

### Recent Developments

UnitedHealth Group has filed its 2026 10-K and 10-Q reports, confirming no material changes to the risk factors previously disclosed in its 2025 annual filing. The company continues to execute its capital return strategy, with recent filings detailing ongoing share repurchase activities during the second quarter of 2026. Investors should monitor these regulatory updates for any emerging operational or financial risks that could impact the stock's current valuation near its 52-week low.

### SEC Filing Highlights
UnitedHealth Group’s profitability, driven by risk-based products comprising nearly 80% of revenue, remains highly sensitive to the accuracy of medical cost predictions and utilization rates. The company faces significant headwinds from unrecoverable cost increases stemming from medical inflation, new technologies, and climate-related factors that often exceed fixed contract premiums. Additionally, Optum Health’s value-based care models carry execution risks, where failure to deliver lower-cost, higher-quality outcomes could materially impact financial positions. Cybersecurity and data integrity also present critical vulnerabilities, particularly following the 2024 Change Healthcare breach and the escalating threat of AI-driven attacks. Consequently, the firm must navigate complex integration challenges and evolving regulatory landscapes regarding health data and artificial intelligence to maintain operational stability.

### Risk Factors

*   **Medical Cost Estimation and Pricing:** Inaccurate estimation of medical costs or benefit designs for risk-based products—which generate nearly 80% of consolidated revenues—could materially adversely affect financial results due to factors like medical inflation, utilization spikes, and regulatory changes.
*   **Cybersecurity and Data Integrity:** The company faces significant exposure to cyberattacks, data breaches, and system failures, including vulnerabilities in third-party vendors and recent high-profile incidents, which could result in operational disruptions, regulatory sanctions, and reputational harm.
*   **Regulatory and Legal Compliance:** Rapidly evolving laws and regulations concerning health data, information technology, and artificial intelligence may impose new compliance burdens, alter the competitive landscape, and negatively impact market competitiveness.

## Audited (Exec Summary + Outlook)

### Executive Summary
UnitedHealth Group is a dominant healthcare conglomerate generating $450.5 billion in annual revenue, with its profitability heavily reliant on risk-based products that comprise nearly 80% of its total revenue. The stock is currently notable for its valuation dynamics, where a trailing P/E of 23.92 contrasts with a forward P/E of 16.45, signaling market expectations for future earnings growth despite a modest 3.14% net profit margin. The single most important near-term variable shaping the investment outcome is the company’s ability to accurately predict medical costs and manage utilization rates amidst persistent medical inflation and regulatory scrutiny.

### Outlook
The directional outlook for UnitedHealth Group is cautiously constructive, anchored by its massive scale and integrated model, yet tempered by significant execution and regulatory risks. Key variables to monitor include the trend in medical cost inflation, the success of Optum Health’s value-based care models in delivering lower-cost outcomes, and the firm’s resilience against evolving cybersecurity threats and AI-driven vulnerabilities. The thesis would be strengthened if the company demonstrates consistent ability to align medical cost predictions with actual utilization rates, thereby protecting its thin net profit margins; conversely, the view would weaken if regulatory pressures regarding health data or artificial intelligence impose unexpected compliance burdens or if cybersecurity incidents disrupt critical operations.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically audit every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "$450.5 billion in annual revenue"
LABEL: SUPPORTED
REASON: The raw source data lists revenue as $450,525,986,816, which rounds to $450.5 billion, and the pre-written Financial Health section states "annual revenue of $450.5 billion."

---

CLAIM: "nearly 80% of its total revenue"
LABEL: SUPPORTED
REASON: Both the RAG SEC Highlights and the pre-written SEC Filing Highlights and Risk Factors sections explicitly state that risk-based products "comprise nearly 80% of total consolidated revenues."

---

CLAIM: "trailing P/E of 23.92"
LABEL: SUPPORTED
REASON: The raw source data lists pe_ratio as 23.916397, which rounds to 23.92, consistent with the pre-written Financial Health section.

---

CLAIM: "forward P/E of 16.45"
LABEL: SUPPORTED
REASON: The raw source data lists forward_pe as 16.448336, which rounds to 16.45, consistent with the pre-written Financial Health section.

---

CLAIM: "modest 3.14% net profit margin"
LABEL: SUPPORTED
REASON: The raw source data lists profit_margin as 0.03135, which rounds to 3.14% (or 3.135%), and the pre-written Financial Health section states "net profit margin of 3.14%"; the rounding difference is within 0.15 percentage points.

---

**OUTLOOK**

The Outlook section contains no specific quantitative figures, price targets, thresholds, ratios, metrics, percentages, named product milestones, or forward-looking numbers. All statements in the Outlook are qualitative and directional in nature (e.g., "cautiously constructive," "massive scale," "thin net profit margins," "consistent ability," "unexpected compliance burdens"). There are no numerical claims to audit beyond those already covered in the Executive Summary.

---

**SUMMARY TABLE**

| # | Claim | Label |
|---|-------|-------|
| 1 | $450.5 billion in annual revenue | SUPPORTED |
| 2 | nearly 80% of total revenue (risk-based products) | SUPPORTED |
| 3 | trailing P/E of 23.92 | SUPPORTED |
| 4 | forward P/E of 16.45 | SUPPORTED |
| 5 | 3.14% net profit margin | SUPPORTED |

All five auditable quantitative claims in the Executive Summary and Outlook are **SUPPORTED** by the source data. No claims were found to be UNSUPPORTED or INFERENCE.
